REPL Stock Rises on FDA's Priority Review for Melanoma Drug BLA
The FDA accepts and grants priority review to Replimune's BLA for RP1 in combination with Opdivo for advanced melanoma. A decision is due on Jul.
Cure Today2d
The Significance of the Subcutaneous Opdivo FDA Approval in Solid Tumors
Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...
Teesside Gazette3d
Middlesbrough FC
Latest Boro transfer news, rumours, opinion, injuries, player interviews, fixture news and more. Breaking Middlesbrough FC news from the Riverside Stadium and Rockcliffe. Latest team news and full ...
BioWorld by Clarivate Releases Comprehensive 2024 Year in Review
BioWorld™ publish (NYSE:CLVT), a leading global provider of transformative intelligence, has released its highly anticipated ...